At the news
? BULLISHIMPACT 8/10 424B5 filed Apr 13, 2026 at 17:26 ET
Spyre Therapeutics is raising $300 million through a common stock offering, following positive Phase 2 topline data for its lead candidate SPY001 in ulcerative colitis. The company reported preliminary cash of $741 million as of March 31, 2026, and has terminated its prior ATM offering. The capital will fund ongoing clinical programs in inflammatory bowel and rheumatic diseases.
- Spyre Therapeutics is offering $300 million of common stock
- Positive Phase 2 topline data for SPY001 in ulcerative colitis showed statistically significant reduction in RHI score of 9.2 points (p<0.0001)
- Company reported preliminary cash of $741 million as of March 31, 2026
- Terminated prior ATM offering in connection with this new offering
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access